Publication details
Erlotinib v 1. linii léčby nemalobuněčného karcinomu plic
| Title in English | Erlotinib in first-line therapy of non-small cell lung cancer |
|---|---|
| Authors | |
| Year of publication | 2013 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Field | Pneumology |
| Keywords | NSCLC; erlotinib; first-line therapy; EURTAC trial |
| Description | Efficacy and safety of erlotinib in first-line therapy of advanced NSCLC with demonstrated activating mutation of EGFR in white European patients was evaluated in the EURTAC trial. Progression-free survival was 9.7 months in patients receiving erlotinib vs. 5.2 months in patients receiving chemotherapy. Response rate was significantly higher in the erlotinib arm, 58% vs. 15% in patients receiving chemotherapy (p < 0.0001). The median of overall survival was 22.9 months in patients receiving erlotinib and 18.8 in patients treated with chemotherapy. Degree 3-4 adverse effects were observed in 45% patients in the erlotinib rm and 81 % in the chemotherapy arm. |